NK cells are activated in amnestic mild cognitive impairment but not in mild Alzheimer's disease patients

Journal of Alzheimer's Disease

Volumn 46, Issue 1, 2015, Pages 93-107

  Le Page, Aurélie ^a   Bourgade, Karine ^a   Lamoureux, Julie ^a   Frost, Eric ^a   Pawelec, Graham ^b   Larbi, Anis ^c   Witkowski, Jacek M ^d   Dupuis, Gilles ^a   Fülöp, Tamás ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c AGENCY FOR SCIENCE   (Singapore)

^d MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Alzheimer's disease; amnestic mild cognitive impairment; cell cytotoxicity; chemotaxis; natural killer cells; phenotyping; toll like receptors

Indexed keywords

AMYLOID BETA PROTEIN; ANTIGEN; CD107 ANTIGEN; CD16 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR7; FAS ANTIGEN; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR BETA1; INTERLEUKIN 12 RECEPTOR BETA2; INTERLEUKIN 18; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; NATURAL KILLER CELL RECEPTOR NKG2A; SECONDARY LYMPHOID TISSUE CHEMOKINE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; APOLIPOPROTEIN E4; CYTOKINE; CYTOKINE RECEPTOR; TLR4 PROTEIN, HUMAN;

AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANTIGEN EXPRESSION; ARTICLE; CELL ACTIVATION; CELL KILLING; CHEMOTAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEGRANULATION; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; INFLAMMATION; INNATE IMMUNITY; MALE; MILD COGNITIVE IMPAIRMENT; NATURAL KILLER CELL; NEUROFIBRILLARY TANGLE; NEUROPSYCHOLOGICAL TEST; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANALYSIS OF VARIANCE; DRUG EFFECTS; FLOW CYTOMETRY; GENETICS; K562 CELL LINE; MENTAL HEALTH; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; APOLIPOPROTEIN E4; CYTOKINES; FEMALE; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-12; K562 CELLS; KILLER CELLS, NATURAL; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; RECEPTORS, CYTOKINE; TOLL-LIKE RECEPTOR 4;

EID: 84929313637     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-143054     Document Type: Article

References (71)

1. Tam JH, Pasternak SH (2012) Amyloid and Alzheimer's disease: Inside and out. Can J Neurol Sci 39, 286-298.
2. Prince M, Jackson J (2009) World Alzheimer report 2009: The global prevalence of dementia, http://www.alz.co.uk/research/files/WorldAlzheimerReport.pdf.
3. Claeysen S, Cochet M, Donneger R, Dumuis A, Bockaert J, Dumuis A, Claeysen S (2012) Alzheimer culprits: Cellular crossroads and interplay. Cell Signal 24, 1831-1840.
4. Kern A, Behl C (2009) The unsolved relationship of brain aging and late-onset Alzheimer disease. Biochim Biophys Acta 1790, 1124-1132.
5. Rao AT, Degnan AJ, Levy LM (2014) Genetics of Alzheimer disease. Am J Neuroradiol 35, 457-458.
6. Piaceri I, Nacmias B, Sorbi S (2013) Genetics of familial and sporadic Alzheimer's disease. Front Biosci (Elite Ed) 5, 167-177.
7. Reitz C, Mayeux R (2014) Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol 88, 640-651.
8. Fulop T, Lacombe G, Cunnane S, Le Page A, Dupuis G, Frost EH, Bourgade-Navarro K, Goldeck D, Larbi A, Pawelec G (2013) Elusive Alzheimer's disease: Can immune signatures help our understanding of this challenging disease? Part 1: Clinical and historical background. Discov Med 15, 23-32.
9. Miklossy J (2011) Emerging roles of pathogens in Alzheimer disease. Expert Rev Mol Med 13, e30.
10. Mawanda F, Wallace R (2013) Can infections cause Alzheimer's disease? Epidemiol Rev 35, 161-180.
11. Geda YE (2012) Mild cognitive impairment in older adults. Curr Psychiatry Rep 14, 320-327.
12. Kelley BJ, Petersen RC (2007) Alzheimer's disease and mild cognitive impairment. Neurol Clin 25, 577-609.
13. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Bäckman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erk-injuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC (2004) Mild cognitive impairment-beyond controversies, towards a consensus: Report of the international working group on mild cognitive impairment. J Intern Med 256, 240-246.
14. Fischer P, Jungwirth S, Zehetmayer S, Weissgram S, Hoenigschnabl S, Gelpi E, Krampla W, Tragl KH (2007) Conversion from subtypes of mild cognitive impairment to Alzheimer dementia. Neurology 68, 288-291.
15. Morris JK, Honea RA, Vidoni ED, Swerdlow RH, Burns JM (2014) Is Alzheimer's disease a systemic disease? Biochim Biophys Acta 1842, 1340-1349.
16. Holmes C (2013) Review: Systemic inflammation and Alzheimer's disease. Neuropathol Appl Neurobiol 39, 51-68.
17. Sardi F, Fassina L, Venturini L, Inguscio M, Guerriero F, Rolfo E, Ricevuti G (2011) Alzheimer's disease, autoimmunity and inflammation. the good, the bad and the ugly. Autoimmun Rev 11, 149-153.
18. Kapadia M, Sakic B (2011) Autoimmune and inflammatory mechanisms of CNS damage. Prog Neurobiol 95, 301-333.
19. Boutajangout A, Wisniewski T (2013) The innate immune system in Alzheimer's disease. Int J Cell Biol 2013, 576383.
20. Butchart J, Holmes C (2012) Systemic and central immunity in Alzheimer's disease: Therapeutic implications. CNS Neurosci Ther 18, 64-76.
21. Heneka MT, Kummer MP, Latz E (2014) Innate immune activation in neurodegenerative disease. Nat Rev Immunol 14, 463-477.
22. Rivest S (2009) Regulation of innate immune responses in the brain. Nat Rev Immunol 9, 429-439.
23. Della Chiesa M, Marcenaro E, Sivori S, Carlomagno S, Pesce S, Moretta A (2014) Human NK cell response to pathogens. Semin Immunol 26, 152-160.
24. Raulet DH, Guerra N (2009) Oncogenic stress sensed by the immune system: Role of natural killer cell receptors. Nat Rev Immunol 9, 568-580.
25. Rodier F, Campisi J (2011) Four faces of cellular senescence. J Cell Biol 192, 547-556.
26. Caligiuri MA (2008) Human natural killer cells. Blood 112, 461-469.
27. Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S (2013) Controlling natural killer cell responses: Integration of signals for activation and inhibition. Annu Rev Immunol 31, 227-258.
28. Krzewski K, Coligan JE (2012) Human NK cell lytic granules and regulation of their exocytosis. Front Immunol 3, Article 335.
29. Chavez-Galan L, Arenas-Del Angel MC, Zenteno E, Chavez R, Lascurain R (2009) Cell death mechanisms induced by cytotoxic lymphocytes. Cell Mol Immunol 6, 15-25.
30. Solana R, Campos C, Pera A, Tarazona R (2014) Shaping of NK cell subsets by aging. Curr Opin Immunol 29, 56-61.
31. Jadidi-Niaragh F, Shegarfi H, Naddafi F, Mirshafiey A (2012) The role of natural killer cells in Alzheimer's disease. Scand J Immunol 76, 451-456.
32. Richartz-Salzburger E, Batra A, Stransky E, Laske C, Kohler N, Bartels M, Buchkremer G, Schott K (2007) Altered lymphocyte distribution in Alzheimer's disease. J Psychiatr Res 41, 174-178.
33. Araga S, Kagimoto H, Funamoto K, Takahashi K (1991) Reduced natural killer cell activity in patients with dementia of the Alzheimer type. Acta Neurol Scand 84, 259-263.
34. Solerte SB1, Fioravanti M, Severgnini S, Locatelli M, Renzullo M, Pezza N, Cerutti N, Ferrari E (1996) Enhanced cytotoxic response of natural killer cells to interleukin-2 in Alzheimer's disease. Dementia 7, 343-348.
35. Solerte SB, Fioravanti M, Pascale A, Ferrari E, Govoni S, Battaini F (1998) Increased natural killer cell cytotoxicity in Alzheimer's disease may involve protein kinase C dysregula-tion. Neurobiol Aging 19, 191-199.
36. Solerte SB, Cerutti N, Severgnini S, Rondanelli M, Ferrari E, Fioravanti M (1998) Decreased immunosuppressive effect of cortisol on natural killer cytotoxic activity in senile dementia of the Alzheimer type. Dement Geriatr Cogn Disord 9, 149-156.
37. Masera RG, Prolo P, Sartori ML, Staurenghi A, Griot G, Ravizza L, Dovio A, Chiappelli F, Angeli A (2002) Mental deterioration correlates with response of natural killer (NK) cell activity to physiological modifiers in patients with short history of Alzheimer's disease. Psychoneuroendocrinol 27, 447-461.
38. Lyons A, Murphy KJ, Clarke R, Lynch MA (2011) Atorvastatin prevents age-related and amyloid-beta-induced microglial activation by blocking interferon-gamma release from natural killer cells in the brain. J Neuroinflammation 8, 27.
39. Pawelec G, Ferguson FG, Wikby A (2001) The SENIEUR protocol after 16 years. Mech Ageing Dev 122, 132-134.
40. Small GW, Rabins PV, Barry PP, Buckholtz NS, DeKosky ST, Ferris SH, Finkel SI, Gwyther LP, Khachaturian ZS, Lebowitz BD, McRae TD, Morris JC, Oakley F, Schneider LS, Streim JE, Sunderland T, Teri LA, Tune LE (1997) Diagnosis and treatment of Alzheimer disease and related disorders. consensus statement of the american association for geriatric psychiatry, the Alzheimer's association, and the american geriatrics society. J Amer Med Assoc 278, 1363-1371.
41. Grundman M1, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR Jr, Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, Jin S, Schultz AN, Schafer K, Mulnard R, van Dyck CH, Mintzer J, Zamrini EY, Cahn-Weiner D, Thal LJ, Alzheimer's Disease Cooperative, Study (2004) Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol 61, 59-66.
42. Monastero R, Mangialasche F, Camarda C, Ercolani S, Camarda R (2009) A systematic review of neuropsychiatric symptoms in mild cognitive impairment. J Alzheimers Dis 18, 11-30.
43. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
44. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL (2005) The Montreal cognitive assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53, 695-699.
45. Aktas E, Kucuksezer UC, Bilgic S, Erten G, Deniz G (2009) Relationship between CD107a expression and cytotoxic activity. Cell Immunol 254, 149-154.
46. Parihar R, Dierksheide J, Hu Y, Carson WE (2002) IL-12 enhances the natural killer cell cytokine response to ab-coated tumor cells. J Clin Invest 110, 983-992.
47. Salani F, Ciaramella A, Bizzoni F, Assogna F, Caltagirone C, Spalletta G, Bossu P (2013) Increased expression of interleukin-18 receptor in blood cells of subjects with mild cognitive impairment and alzheimer's disease. Cytokine 61, 360-363.
48. Chalifour A, Jeannin P, Gauchat JF, Blaecke A, Malissard M, N'Guyen T, Thieblemeont T, Delneste Y (2004) Direct bacterial protein PAMP recognition by human NK cells involves TLRs and triggers alpha-defensin production. Blood 104, 1778-1783.
49. Hart OM, Athie-Morales V, O'Connor GM, Gardiner CM (2005) TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-y production. J Immunol 175, 1636-1642.
50. Lauzon NM, Mian F, MacKenzie R, Ashkar AA (2006) The direct effects of toll-like receptor ligands on human NK cell cytokine production and cytotoxicity. Cell Immunol 241, 102-112.
51. Udan ML, Ajit D, Crouse NR, Nichols MR (2008) Toll-like receptors 2 and 4 mediate Aβ(1-42) activation of the innate immune response in a human monocytic cell line. J Neu-rochem 104, 524-533.
52. Amarante MK, Watanabe MA (2010) Toll-like receptor 3: Involvement with exogenous and endogenous RNA. Int Rev Immunol 29, 557-573.
53. Maghazachi AA (2010) Role of chemokines in the biology of natural killer cells. Curr Top Microbiol Immunol 341, 37-58.
54. Hamann I, Unterwalder N, Cardona AE, Meisel C, Zipp F, Ransohoff RM, Infante-Duarte C (2011) Analyses of pheno-typic and functional characteristics of CX3CR1-expressing natural killer cells. Immunology 133, 62-73.
55. Infante-Duarte C, Weber A, Kratzschmar J, Prozorovski T, Pikol S, Hamann I, Bellmann-Strobl J, Aktas O, Dörr J, Wuer-fel J, Stürzebecher CS, Zipp F (2005) Frequency of blood CX3CR1-positive natural killer cells correlates with disease activity inmultiple sclerosis patients.FASEB J19, 1902-1904.
56. Huang D, Shi FD, Jung S, Pien GC, Wang J, Salazar-Mather TP, He TT, Weaver JT, Ljunggren HG, Biron CA, Littman DR, Ransohoff RM (2006) The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J 20, 896-905.
57. Forster R, Davalos-Misslitz AC, Rot A (2008) CCR7 and its ligands: Balancing immunity and tolerance. Nat Rev Immunol 8, 362-371.
58. Mandelboim O, Malik P, Davis DM, Jo CH, Boyson JE, Strominger JL (1999) Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proc Natl Acad Sci U S A 96, 5640-5644.
59. Streit WJ, Xue QS (2014) Human CNS immune senescence and neurodegeneration. Curr Opin Immunol 29, 93-96.
60. Motta M, Imbesi R, Di Rosa M, Stivala F, Malaguarnera L (2007) Altered plasma cytokine levels in Alzheimer's disease: Correlation with the disease progression. Immunol Lett 114, 46-51.
61. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S (2008) Functions of natural killer cells. Nat Immunol 9, 503-510.
62. Liu S, Liu Y, Hao W, Wolf L, Kiliaan AJ, Penke B, Rübe CE, Walter J, Heneka MT, Hartmann T, Menger MD, Fassbender K (2012) TLR2 is a primary receptor for Alzheimer's amyloid beta peptideto trigger neuroinflammatory activation. J Immunol 188, 1098-1107.
63. Ishii KJ, Akira S (2006) Innate immune recognition of, and regulation by, DNA. Trends Immunol 27, 525-532.
64. Doi Y, Mizuno T, Maki Y, Jin S, Mizoguchi H, Ikeyama M, Doi M, Michikawa M, Takeuchi H, Suzumura A (2009) Microglia activated with the toll-like receptor 9 ligand CpG attenuate oligomeric amyloid β neurotoxicity in in vitro and in vivo models of Alzheimer's disease. Am J Pathol 175, 2121-2132.
65. Scholtzova H, Kascsak RJ, Bates KA, Boutajangout A, Kerr DJ, Meeker HC, Mehta PD, Spinner DS, Wisniewski T (2009) Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology. J Neurosci 29, 1846-1854.
66. Frey C, Bonert A, Kratzsch T, Rexroth G, Rösch W, Müller-Spahn F, Maurer K, Müller WE, Eckert A (2006) Apolipoprotein E epsilon 4 is associated with an increased vulnerability to cell death in Alzheimer's disease. J Neural Transm113, 1753-1761.
67. Milush JM, Lopez-Verges S, York VA, Deeks SG, Martin JN, Hecht FM, Lanier LL, Nixon DF (2013) CD56negCD16+ NK cells are activated mature NK cells with impaired effector function during HIV-1 infection. Retrovirol 10, 158.
68. Bhat R, Watzl C (2007) Serial killing of tumor cells by human natural killer cells-enhancement by therapeutic antibodies. PLoS One 2, e326.
69. Jiang Y, Zhou F, Tian Y, Zhang Z, Kuang R, Liu J, Han X, Hu Q, Xu J, Shang H (2013) Higher NK cell IFN-y production is associated with delayed HIV disease progression in LTNPs. J Clin Immunol 33, 1376-1385.
70. Aggarwal A, Sharma A, Bhatnagar A (2013) Bi(o)communications among peripheral blood fractions: A focus on NK and NKT cell biology in rheumatoid arthritis. Autoimmunity 46, 238-250.
71. dimCD16+ NK cell-like phenotype and correlates with HIV viral load. PLoS One 7, e44820.